Table 1.
Characteristics of the study population by prophylaxis group
| Characteristic | Fluconazole group (n = 65) | Posaconazole group (n = 65) | P-value |
|---|---|---|---|
| Age, years | |||
| Mean + SD | 60.2 + 14.4 | 58.9 + 14.7 | 0.631 |
| Median (range) | 65 (22–83) | 62 (21–82) | |
| Gender, number of patients (%) | |||
| Male | 42 (64.6) | 43 (66.2) | 0.85 |
| Female | 23 (35.4) | 22 (33.9) | |
| Total cytarabine dosage during admission (mg), mean ± SD | 680.1 ± 1007.9 | 1330.1 ± 2101.2 | 0.026 |
| Duration of prophylaxis (days), mean ± SD | 15.7 ± 8.9 | 18.2 ± 9.4 | 0.12 |
| Duration of neutropenia (PMN <500/mm2, days), mean ± SD | 24.2 ± 10.6 | 25.9 ± 11.6 | 0.36 |
| Race, number of patients (%) | |||
| Caucasian | 54 (83.8) | 52 (80.0) | |
| African–American | 7 (10.8) | 10 (15.4) | |
| Asian | 1 (1.5) | 2 (3.1) | |
| Native American | 2 (3.1) | 1 (1.5) | |
| Others | 1 (1.5) | 0 (0) | |
| First reinduction leukemia, no (%) | 3 (4.6) | 14 (21.6) | 0.00772 |
| Secondary leukemia, no (%) | 26 (40.0) | 19 (29.2) | 0.20 |
| Chronic kidney disease, number of patients (%) | 5 (7.7) | 4 (6.2) | 1.002 |
| Chronic obstructive pulmonary disease, number of patients (%) | 3 (4.6) | 1 (1.5) | 0.622 |
| Diabetes mellitus, number of patients (%) | 9 (13.9) | 11 (16.9) | 0.63 |
1
Student's t-test for independent samples (two-sided) for continuous variables.
2
Fishers's exact test (two-sided) for small numbers of categorical variable, others: chi-square test.